Arbutus Biopharma (ABUS) AI Stock Analysis

• Market Cap: $892.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: 116.64%
• EPS Growth: 47.93%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 192,324,020
• 10 Day Avg. Volume: 1,292,089
• 30 Day Avg. Volume: 1,107,593
• PEG Ratio: 0.64
• Price to Book (P/B): 6.23
• Price to Sales (P/S): 98.35
• P/FCF Ratio: -9.33
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 53.51
• Enterprise Value/Gross Profit: -246.24
• Enterprise Value/Ebitda: -17.51
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.18
• Revenue Forecast (FY): $14.00M

• Rating: 49 Neutral
• Price Target: $4.50 ▲(2.04% Upside)

Arbutus Biopharma's overall stock score is primarily impacted by its poor financial performance, with significant losses and cash flow challenges. While technical indicators show some strength, the negative valuation metrics and ongoing legal proceedings present risks. Positive developments in clinical trials offer potential upside.

Positive Factors

Clinical Trial Progress

Successful clinical trials are crucial for advancing drug candidates, potentially leading to regulatory approval and commercialization, which can drive long-term revenue growth.

Cash Position

A robust cash position provides financial flexibility to fund ongoing research and development, supporting the company's long-term strategic initiatives.

Patent Litigation

Successful litigation could result in significant compensation, enhancing financial stability and reinforcing Arbutus's competitive position in the biotechnology sector.

Negative Factors

Profitability Challenges

Persistent profitability challenges can hinder the company's ability to reinvest in growth opportunities and may impact long-term financial sustainability.

Negative Cash Flow

Ongoing negative cash flow can strain resources, limiting the company's ability to invest in R&D and potentially affecting future growth prospects.

Revenue Decline

Declining revenue growth suggests challenges in market penetration and product adoption, which could impact long-term business viability.

Arbutus Biopharma Business Overview & Revenue Model

Company Description

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of viral diseases, particularly hepatitis B (HBV) and other viral infections. The company's core products include a range of RNA interference (RNAi) therapies and other novel antiviral compounds aimed at addressing unmet medical needs in the field of infectious diseases. Arbutus leverages its proprietary technology platforms to advance its drug candidates through various stages of clinical development.

How the Company Makes Money

Arbutus Biopharma generates revenue primarily through collaboration agreements, government grants, and potential milestone payments from its partnerships. The company collaborates with larger pharmaceutical companies to co-develop its drug candidates, which can provide upfront payments, shared research costs, and milestone payments based on the achievement of development goals. Additionally, if any of its products receive regulatory approval and are commercialized, Arbutus would earn royalties on sales. Their revenue model is heavily dependent on the successful advancement of their clinical programs and the strategic partnerships they establish with industry players to enhance development capabilities and market reach.

Arbutus Biopharma Financial Statement Overview

Summary

Arbutus Biopharma faces significant financial challenges, with persistent losses and negative cash flows. Despite a notable revenue growth rate, the company struggles with profitability and cash flow issues. The balance sheet remains stable with low leverage, providing some resilience against financial instability.

Income Statement

Arbutus Biopharma's income statement reveals significant challenges. Despite a notable revenue growth rate of 140.76% in the TTM, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has also declined compared to previous periods, indicating potential issues in cost management or pricing strategy.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating returns for shareholders. The equity ratio remains stable, indicating a solid capital structure despite operational challenges.

Cash Flow

Cash flow analysis highlights a concerning trend with negative operating and free cash flows, although there is a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to reported earnings. The free cash flow to net income ratio is slightly above 1, suggesting cash flow is aligned with net income despite being negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.61M	6.17M	18.14M	39.02M	10.99M	6.91M
Gross Profit	-3.17M	6.17M	18.14M	39.02M	10.99M	-40.57M
EBITDA	-44.65M	-68.40M	-70.99M	-61.86M	-71.64M	-57.76M
Net Income	-42.28M	-69.92M	-72.85M	-69.46M	-76.25M	-63.74M
Balance Sheet
Total Assets	97.71M	131.71M	144.40M	195.42M	204.49M	137.08M
Cash, Cash Equivalents and Short-Term Investments	93.70M	122.62M	126.00M	146.91M	155.32M	123.27M
Total Debt	922.00K	1.29M	8.72M	12.55M	18.91M	22.54M
Total Liabilities	20.31M	34.34M	38.38M	58.57M	35.05M	35.11M
Stockholders Equity	77.40M	97.37M	106.02M	136.85M	169.44M	101.97M
Cash Flow
Free Cash Flow	-45.36M	-65.03M	-86.94M	-35.87M	-68.34M	-51.67M
Operating Cash Flow	-45.27M	-64.85M	-85.94M	-35.36M	-67.53M	-51.44M
Investing Cash Flow	30.35M	22.95M	50.77M	-74.94M	-12.68M	-14.91M
Financing Cash Flow	5.50M	52.00M	30.65M	31.81M	137.24M	86.75M

Arbutus Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABUS, the sentiment is Positive. The current price of 4.41 is below the 20-day moving average (MA) of 4.45, below the 50-day MA of 4.47, and above the 200-day MA of 3.75, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 55.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABUS.

Arbutus Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	58 Neutral	$6.65B	-20.87	-75.20%	―	364.98%	-25.33%
IMTX	56 Neutral	$1.33B	-8.75	-29.01%	―	-27.61%	-69.49%
IMNM	56 Neutral	$1.81B	-6.75	-93.04%	―	-4.44%	63.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GERN	51 Neutral	$893.70M	-11.15	-29.57%	―	522.13%	62.68%
ABUS	49 Neutral	$892.38M	-20.47	-45.88%	―	116.64%	47.93%
SANA	33 Underperform	$1.27B	-4.64	-96.11%	―	―	31.16%

Arbutus Biopharma Corporate Events

Arbutus Biopharma CEO Discusses Lawsuits Over LNP Technology

On December 11, 2025, Lindsay Androski, CEO of Arbutus Biopharma, presented at Roivant Sciences Ltd.’s Investor Day regarding ongoing lawsuits against Moderna, Pfizer, and BioNTech for using Arbutus’s patented LNP technology in COVID-19 vaccines. The litigation involves claims of patent infringement, with court hearings expected in 2026. Arbutus’s legal actions aim to secure compensation for the unauthorized use of their technology, which has been integral to the development of Moderna’s and Pfizer/BioNTech’s vaccines. The outcome of these lawsuits could significantly impact Arbutus’s financial position and its standing in the biotechnology sector.

Arbutus Biopharma Reports Strong Q3 Financial Results

On November 13, 2025, Arbutus Biopharma reported its third quarter financial results, highlighting a strong financial position with $93.7 million in cash and marketable securities. The company announced significant progress in its clinical trials for imdusiran, with 46% of Phase 2a patients meeting criteria to discontinue treatment and 94% of long-term follow-up patients remaining off treatment for over two years. Arbutus is also involved in ongoing litigation with Moderna and Pfizer/BioNTech over its LNP technology, with a favorable ruling in the Pfizer-BioNTech case and a trial against Moderna set for March 2026. Financially, the company reported a net loss of $7.7 million for the quarter, a decrease from the previous year, due to cost-cutting measures and a focus on advancing clinical development.

Arbutus Biopharma Showcases Data at Liver Meeting 2025

On October 7, 2025, Arbutus Biopharma announced that four abstracts featuring data on their products imdusiran and AB-101 were accepted for presentation at the American Association for the Study of Liver Diseases – The Liver Meeting 2025. The AB-101 abstract was notably selected as a Poster of Distinction. These presentations highlight the safety and potential efficacy of imdusiran in enhancing treatment responses in chronic hepatitis B patients and the promising pharmacodynamics of AB-101, which may strengthen Arbutus’s position in the biopharmaceutical industry focused on infectious diseases.